Recent approaches in the treatment of Hodgkin's lymphoma.
An aim has been to find the optimal therapeutic approach for each patient suffering from Hodgkin's lymphoma. The disease with 80% curability rate presents the great success of clinical oncology. There is no doubt that the development and improvement of therapeutic approaches described in this article has contributed to the excellent results achieved in the last twenty years. But a lot of problems still remain to be solved by haemato-oncologists despite such progress in the treatment. The most important tasks are: 1. to increase the curability of advanced stages, 2. to improve therapeutic results in refractory and relapsing patients, 3. to eliminate or decrease the late toxicity particularly in the favourable early and intermediate stages.
Raida
L
L
Haemato-oncology Department of University Hospital, Olomouc, Czech Republic.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging
D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor